BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haist M, Mailänder V, Bros M. Nanodrugs Targeting T Cells in Tumor Therapy. Front Immunol 2022;13:912594. [PMID: 35693776 DOI: 10.3389/fimmu.2022.912594] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen J, Cong X. Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects. Biomed Pharmacother 2023;157:113998. [PMID: 36399829 DOI: 10.1016/j.biopha.2022.113998] [Reference Citation Analysis]
2 Katopodi T, Petanidis S, Tsavlis D, Anestakis D, Charalampidis C, Chatziprodromidou I, Eskitzis P, Zarogoulidis P, Kosmidis C, Matthaios D, Porpodis K. Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy. Front Oncol 2022;12:1042125. [DOI: 10.3389/fonc.2022.1042125] [Reference Citation Analysis]
3 Duan Q, Hu T, Zhu Q, Jin X, Chi F, Chen X. How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development. Front Immunol 2022;13:974433. [DOI: 10.3389/fimmu.2022.974433] [Reference Citation Analysis]
4 Mamun AA, Uddin MS, Perveen A, Jha NK, Alghamdi BS, Jeandet P, Zhang HJ, Ashraf GM. Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments. Semin Cancer Biol 2022;86:101-16. [PMID: 36084815 DOI: 10.1016/j.semcancer.2022.08.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]